Less than a tenth of people who could benefit from weight-loss injections including Wegovy can access them, warns the World Health Organization as it releases its inaugural guidance on the therapies.
With in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for more widespread and fairer access to this class of drugs.
Based on estimates, more than two billion are projected to be living with obesity by 2030 if no action is taken.
"The latest guidelines recognises that obesity is a long-term condition that can be managed with comprehensive and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are significant hurdles to broad availability to the jabs that can assist patients in reducing substantial body mass, notes the organization.
Skinny Jab Scarcity
Despite the present most optimistic scenario, the manufacturing of such drugs could only cover about 100 million people – fewer than 10% of eligible patients, per the health organization.
The recommendation calls on countries and companies to increase availability, through strategies including licensing agreements.
A patent on a key compound – the primary component of a leading brand – is set to lapse in several countries in 2026.
The Way Obesity Drugs Operate
These medications imitate a biological compound to slow digestion, reduce hunger and boost feelings of fullness so users eat less.
Patients typically begin shedding pounds in the initial weeks of starting on the once-weekly jabs.
Studies indicates people may put most of the weight back on after a year of halting the treatment, when their typical hunger resume.
To be above a healthy weight increases your chance for developing health problems, including type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity affects individuals in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, as per the health agency.
